Gantenbein, Andreas R; Agosti, Reto; Gobbi, Claudio; Flügel, Dominique; Schankin, Christoph J.; Viceic, Dragana; Zecca, Chiara; Pohl, Heiko (2021). Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia, 41(11-12), pp. 1181-1186. Sage Publications 10.1177/03331024211014616
|
Text
Gantenbein__2021__Impact_on_monthly_migraine_days.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (447kB) | Preview |
OBJECTIVE
This study aims to analyse the effect of the discontinuation of anti-calcitonin gene-related peptide antibodies on monthly migraine days after 12 treatment months.
BACKGROUND
Anti-calcitonin gene-related peptide antibodies have been a game changer in migraine prophylaxis. However, high treatment costs warrant reducing treatment duration to the essential minimum.
METHODS
We collected data of patients with migraine who had received anti-calcitonin gene-related peptide antibodies and had received treatment for 12 months.
RESULTS
We included 52 patients. The average number of monthly migraine days was 16 ± 7 days at baseline, 6 ± 6 in the third, and 5 ± 4 in the 12th treatment month. After treatment interruption, the number of monthly migraine days was 6 ± 4 days in the first month, 9 ± 4 days in the second, and 11 ± 5 days in the third month. Most patients (88.9%) restarted treatment.
CONCLUSION
Only little of the therapeutic effect of anti-calcitonin gene-related peptide antibodies outlasts their pharmacological effect. After treatment interruption, migraine frequency rose in most patients, and prophylaxis was required again in most cases.Limiting treatment to benefitting patients and confirming the need for prophylaxis periodically is reasonable. However, our data does not support the need for prescheduled treatment discontinuation after 12 months and a fixed duration of the treatment interruption of 3 months.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Schankin, Christoph Josef |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0333-1024 |
Publisher: |
Sage Publications |
Language: |
English |
Submitter: |
Chantal Kottler |
Date Deposited: |
26 Jul 2021 14:50 |
Last Modified: |
05 Dec 2022 15:52 |
Publisher DOI: |
10.1177/03331024211014616 |
PubMed ID: |
34000847 |
Uncontrolled Keywords: |
Erenumab burden of disease galcanezumab treatment interruption |
BORIS DOI: |
10.48350/157653 |
URI: |
https://boris.unibe.ch/id/eprint/157653 |
Actions (login required)
 |
Edit item |